Subjective assessment of brexpiprazole in patients with schizophrenia: a prospective observational study
Fujita Medical Journal · 2023-08 · 9 (3) · 231-235
DOI: 10.20407/fmj.2022-031 ↗Kurz gefasst
Fachartikel in der Zeitschrift Fujita Medical Journal, 2023-08. Verfasst von Rina Yokoi und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacotherapeutics and Informatics, Fujita Health University, School of Medicine, Toyoake, Aichi, Japan. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Objectives
To investigate the subjective assessments of an antipsychotic treatment with brexpiprazole.
Methods
This was a 14-week prospective observational study. Nineteen patients participated in the study between February 2019 and January 2020.
Results
Patients had a mean age of 40.6±14.2 years and a Clinical Global Impressions-Severity of Illness scale (CGI-S) score of 4.6±1.2 at the initiation of brexpiprazole treatment. The Subjective Well-being under Neuroleptic drug treatment Short form, Japanese version (SWNS-J) total score significantly improved from 68.1±22.3 in week 2 to 79.5±21.0 in week 14 (p=0.0084). The SWNS-J subscales of self-control and social integration status also significantly improved from 14.0±4.7 and 13.9±6.0 in week 2 to 17.0±4.7 and 16.0±5.1 in week 14, respectively (p=0.0053 and 0.012, respectively). No significant improvements were observed in any other SWNS-J subscales or the Drug Attitude Inventory-10 (DAI-10) in the 14-week observation period. Moreover, the SWNS-J total score did not correlate with the DAI-10 (r=0.31, p=0.19), or CGI-S (r=–0.18, p=0.47) scores.
Conclusions
The present results suggest that brexpiprazole might improve subjective well-being, although this may not necessarily reflect psychopathological improvements. To enhance medication adherence, it is important to perform subjective assessments on patients over time.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Pharmacotherapeutics and Informatics, Fujita Health University, School of Medicine, Toyoake, Aichi, Japan.
- Office of Clinical Pharmacy Practice and Health Care Management, Faculty of Pharmacy, Meijo University, Nagoya, Aichi, Japan.
- Department of Psychiatry, Fujita Health University, School of Medicine, Toyoake, Aichi, Japan.
Zitieren
APA
Yokoi, R., Hatano, M., Kamei, H., Morita, A., Hanya, M., Iwata, N., & Yamada, S. (2023). Subjective assessment of brexpiprazole in patients with schizophrenia: a prospective observational study. Fujita Medical Journal, 9(3), 231-235. https://doi.org/10.20407/fmj.2022-031
Vancouver
Yokoi R, Hatano M, Kamei H, Morita A, Hanya M, Iwata N, et al. Subjective assessment of brexpiprazole in patients with schizophrenia: a prospective observational study. Fujita Medical Journal. 2023;9(3):231-235. doi:10.20407/fmj.2022-031
BibTeX
@article{Yokoi2023,
author = {Yokoi, Rina and Hatano, Masakazu and Kamei, Hiroyuki and Morita, Aoi and Hanya, Manako and Iwata, Nakao and Yamada, Shigeki},
title = {Subjective assessment of brexpiprazole in patients with schizophrenia: a prospective observational study},
journal = {Fujita Medical Journal},
year = {2023},
volume = {9},
number = {3},
pages = {231--235},
doi = {10.20407/fmj.2022-031}
}
EUVIMED